Print

Purpose

The main purpose of this study is to determine if participants who previously took donanemab get clinical benefit when they receive annual doses. For each participant, the study will last up to 2.5 years and will include 6 visits.

Conditions

Eligibility

Eligible Ages
Over 55 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Have completed study AACM Addendum 7. - Have a reliable study partner and backup study partner familiar with overall function and behavior, such as day-to-day activities and cognitive abilities. - Are individuals assigned female at birth who are not of childbearing potential, or are individuals assigned male at birth. - Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion Criteria

  • Current serious or unstable illnesses that, in the investigator's opinion, could interfere with participation in this study. - Have any contraindications for magnetic resonance imaging (MRI), including claustrophobia or the presence of contraindicated metal (ferromagnetic) implants/cardiac pacemaker. - Have any intracranial abnormality or lesion, including but not limited to macrohemorrhage, inflammation, or structural findings that, in the opinion of the investigator, may pose an unacceptable safety risk to the participant. Screening MRI finding of amyloid-related imaging abnormalities with edema (ARIA-E) may be monitored for resolution. - Contraindication to florbetapir F 18 PET. - Have had history of amyloid-targeting therapy treatment outside donanemab trials. - Have participated, within the last 30 days, in a clinical trial involving a study intervention judged not to be scientifically or medically compatible with this study.

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
Double (Participant, Investigator)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Donanemab 		Donanemab administered intravenously (IV)
  • Drug: Donanemab
    Administered IV
Placebo Comparator
Placebo 		Placebo IV
  • Drug: Placebo
    Administered IV

Recruiting Locations

Irvine Clinical Research
Irvine, California 92614
Contact:
9497531663

Healthy Brain Clinic
Long Beach, California 90804
Contact:
562-606-5999

Syrentis Clinical Research
Santa Ana, California 92705
Contact:
714-542-3008

Providence Medical Foundation
Santa Rosa, California 95403
Contact:
7075213830

VIN - Aventura
Aventura, Florida 33180
Contact:
305-933-5993

Bradenton Research Center, Inc.
Bradenton, Florida 34205
Contact:
9417080005

K2 Medical Research ORLANDO
Maitland, Florida 32751
Contact:
407-500-5252

Charter Research - Orlando
Orlando, Florida 32803
Contact:
407-337-3000

Emerald Coast Neurology - Airport Boulevard
Pensacola, Florida 32504
Contact:
8504381136

Charter Research - The Villages
The Villages, Florida 32162
Contact:
352-441-2000

Northwest Clinical Trials
Boise, Idaho 83704
Contact:
2086850600

Josephson Wallack Munshower Neurology, PC
Indianapolis, Indiana 46256
Contact:
3175376099

Vector Clinical Trials
Las Vegas, Nevada 89128
Contact:
702-750-000

Gadolin Research
Beaumont, Texas 77702
Contact:
409-331-6040

Northwest Clinical Research Center
Bellevue, Washington 98007

Universal Research Group
Tacoma, Washington 98405
Contact:
253-882-1070

More Details

Status
Recruiting
Sponsor
Eli Lilly and Company

Study Contact

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
1-317-615-4559
LillyTrials@Lilly.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.